Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FSH Clear all
Completed Phase 3 Interventional

Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF

NCT00378001
View directory record Official record
Conditions
Infertility
Interventions
FSH-IBSA, GONAL-F
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 6, 2026, 4:51 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women

NCT00334971
View directory record Official record
Conditions
Healthy, Fragile X Syndrome
Interventions
Follicle Aspiration
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Terminated Early Phase 1 Interventional

The Effect of DHEA on Markers of Ovarian Reserve in Women With Diminished Ovarian Reserve

NCT01129830
View directory record Official record
Conditions
Infertility
Interventions
dehydroepiandrosterone
Dietary Supplement
Lead sponsor
Virginia Center for Reproductive Medicine
Other
Eligibility
21 Years to 44 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

NCT01687712
View directory record Official record
Conditions
Infertility
Interventions
AFOLIA, Gonal-f® RFF
Drug
Lead sponsor
Fertility Biotech AG
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Tempe, Arizona • Encino, California • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

NCT00064987
View directory record Official record
Conditions
Hypogonadism, Kallmann Syndrome
Interventions
Testicular biopsy, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH)
Procedure · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development

NCT01422395
View directory record Official record
Conditions
Fertility
Interventions
Freezing
Procedure
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mono-menotropins Versus rFSH Protocol on Embryo Quality

NCT02418533
View directory record Official record
Conditions
Infertility, Fertility
Interventions
menotropin, Recominant Follicle Stimulating Hormone (rFSH)
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 38 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

TMS-Induced LH Response in Healthy Women in Luteal Phase

NCT07363421
View directory record Official record
Conditions
Healthy Women
Interventions
Transcranial Magnetic Stimulation Active, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
The City College of New York
Other
Eligibility
22 Years to 40 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

NCT00614406
View directory record Official record
Conditions
Ovulation (Follicular Rupture Yes/no), Menstrual Cycles (Total Length, Bleeding Days), Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Interventions
Celebrex, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Study for Development of an Early Test for Ovarian Failure

NCT00006156
View directory record Official record
Conditions
Healthy, Premature Ovarian Failure
Interventions
Control, Drug: FSH
Other · Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) Glycosylation in Women: Effect of Estradiol

NCT03868202
View directory record Official record
Conditions
Follicle Stimulating Hormone Glycosylation, Urinary FSH21/FSH24 Ratio, Estradiol Effect
Interventions
Estradiol Transdermal Product
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

NCT03738618
View directory record Official record
Conditions
Infertility, Female
Interventions
Follitropin delta, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Administration of Follicle-stimulating Hormone (FSH) and Low Dose Human Chorionic Gonadotropin (hCG) for Oocyte Maturity While Decreasing hCG Exposure in In Vitro Fertilization (IVF) Cycles

NCT02310919
View directory record Official record
Conditions
Infertility
Interventions
Low dose hCG plus FSH co-trigger, Standard dose of hCG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 6, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 72 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women

NCT01340521
View directory record Official record
Conditions
Infertility
Interventions
Clomiphene Citrate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 1994
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Follicle-Stimulating Hormone (FSH) and the Onset of Puberty

NCT00734279
View directory record Official record
Conditions
Delayed Puberty, Precocious Puberty
Interventions
Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924
View directory record Official record
Conditions
FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH
Interventions
AOC 1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808
View directory record Official record
Conditions
Egg Donation
Interventions
Follistim, Ganirelix, Menotropins, Leuprolide, Transvaginal ultrasound guided needle aspiration of oocytes
Drug · Procedure
Lead sponsor
Michigan Reproductive Medicine
Other
Eligibility
18 Years to 28 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 6, 2026, 4:51 PM EDT
Recruiting Phase 1 Interventional

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

NCT05316129
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Follicle Stimulating Hormone Receptor T Cells
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 6, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS

NCT03252223
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Healthy, Anovulation, Hyperandrogenism
Interventions
Recombinant Follicle Stimulating Hormone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 6, 2026, 4:51 PM EDT